Author:
Terheyden Patrick,Krackhardt Angela,Eigentler Thomas
Publisher
Deutscher Arzte-Verlag GmbH
Reference39 articles.
1. Ribas A, Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science 2018; 359: 1350–5
2. Hodi FS, O‘Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711–23
3. Selby MJ, Engelhardt JJ, Quigley M, et al.: Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res 2013; 1: 32–42
4. Arce Vargas F, Furness AJS, Litchfield K, et al.: Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 2018; 33: 649–63 e4.
5. Schadendorf D, Hodi FS, Robert C, et al.: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015; 33: 1889–94
Cited by
18 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献